A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

✍ Scribed by Spreafico, Anna; Chi, Kim N.; Sridhar, Srikala S.; Smith, David C.; Carducci, Michael A.; Kavsak, Peter; Wong, Tracy S.; Wang, Lisa; Ivy, S. Percy; Mukherjee, Som Dave; Kollmannsberger, Christian K.; Sukhai, Mahadeo A.; Takebe, Naoko; Kamel-Reid, Suzanne; Siu, Lillian L.; Hotte, Sebastien J.

• Book ID: 125358949
• Publisher: Springer US
• Year: 2014
• Tongue: English
• Weight: 518 KB
• Volume: 32
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/s10637-014-0106-5